Open AccessMultiple effects of amprenavir against Candida albicans
Author(s) -
BragaSilva Lys A.,
Mogami Sheijy S.V.,
Valle Roberta S.,
SilvaNeto Ignácio D.,
Santos André L.S.
Publication year - 2010
Publication title -
fems yeast research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.991
H-Index - 92
eISSN - 1567-1364
pISSN - 1567-1356
DOI - 10.1111/j.1567-1364.2009.00595.x
Subject(s) - amprenavir , biology , candida albicans , microbiology and biotechnology , glycoconjugate , corpus albicans , sialic acid , virulence , biofilm , aspergillus fumigatus , fungal protein , enzyme , biochemistry , bacteria , saccharomyces cerevisiae , yeast , gene , protease , genetics , hiv 1 protease
Secreted aspartyl peptidases (Saps) are virulence attributes produced by Candida albicans that participate in multiple aspects of the fungal biology and pathogenesis. In the present paper, we have shown that amprenavir, a peptidase inhibitor used in HIV chemotherapy, inhibited Sap2 and growth of C. albicans and also promoted ultrastructural alterations. Esterase activity, sterol content, biofilm formation and the expression of surface mannose‐ and sialic acid‐rich glycoconjugates were also reduced by amprenavir.